1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow lenabasum: new trials by email Literature Review of lenabasum trials Research Report on lenabasum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Lenabasum 20 mg, Lenabasum 5 mg, Placebo - Dermatomyositis | Phase 3 | Completed | Corbus Pharmaceuticals Inc. | 176 | 2018-12-17 | 2022-08-16 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule - Diffuse Cutaneous Systemic Sclerosis | Phase 3 | Terminated | Corbus Pharmaceuticals Inc. | 365 | 2017-12-18 | 2021-03-29 |
Dermatomyositis (1) · Scleroderma, Diffuse (1)
Corbus Pharmaceuticals Inc. (2)
Canada (2) · Germany (2) · Japan (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · Bulgaria (1) · Czechia (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1)
Chester V Oddis, MD (1) · Chris Denton, MD (1) · Robert Spiera, MD (1) · Victoria P Werth, MD (1)